Ultragenyx Pharmaceutical... (RARE)
NASDAQ: RARE
· Real-Time Price · USD
31.21
0.31 (1.00%)
At close: Oct 03, 2025, 3:59 PM
30.61
-1.92%
After-hours: Oct 03, 2025, 06:56 PM EDT
1.00% (1D)
| Bid | 30.05 |
| Market Cap | 3.01B |
| Revenue (ttm) | 610.16M |
| Net Income (ttm) | -532.93M |
| EPS (ttm) | -5.48 |
| PE Ratio (ttm) | -5.7 |
| Forward PE | -8.49 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 31.3 |
| Volume | 1,337,239 |
| Avg. Volume (20D) | 2,159,350 |
| Open | 31.04 |
| Previous Close | 30.90 |
| Day's Range | 30.82 - 31.62 |
| 52-Week Range | 25.81 - 57.99 |
| Beta | 0.21 |
| Ex-Dividend Date | n/a |
About RARE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RARE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RARE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsUltragenyx Pharmaceutical Inc. is scheduled to release its earnings on
Nov 4, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-3.01%
Ultragenyx Pharmaceutical shares are trading lower...
Unlock content with
Pro Subscription
5 months ago
-4.68%
RARE stock has given up its prior gain. Ultragenyx Pharmaceutical shares were trading higher after the company reported better-than-expected Q1 EPS results.
1 month ago · fool.com
Ultragenyx (RARE) Q2 Revenue Up 13%Ultragenyx (RARE) Q2 Revenue Up 13%
1 month ago · seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call TranscriptUltragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Emil D. Kakkis - Founder, President, CEO & Director Eric Crombez - Chief M...
2 months ago · seekingalpha.com
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 CatalystUltragenyx's 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. UX143's Phase 3 trial continues for scientific rigor, not due to failure; pivotal da...
